Table 1.
Features of included studies.
| Study | Year | Country | Study | Case | Age (Years) | Cancer | Stage | Treatment | Cut-off | Determine the | COX | Survival Analysis | SQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Design | Number | Type | (g/L) | cut-off value | |||||||||
| Yuk | 2019 | South Korea | RTP, SC | 610 | - | BCa | Non-metastatic | Surgery | 1.1 | ROC | mul | OS, CSS, PFS | 8 |
| Li | 2019 | China | RTP, SC | 885 | 67.0 ± 10.6 | UTUC | Non-metastatic | Surgery | 1.23 | ROC | mul | OS, CSS, PFS | 8 |
| Ikeda | 2019 | Japan | RTP, SC | 243 | 61 (55–67) | RCC | Non-metastatic | Surgery | 1.42 | Youden index | mul | CSS | 8 |
| Ha | 2019 | South Korea | RTP, SC | 118 | 69 (60–74) | BCa | Non-metastatic | Surgery | 1.3 | ROC | mul | OS, CSS, PFS | 7 |
| Nishikawa | 2018 | Japan | RTP, SC | 135 | 69 (52–86) | UTUC | Non-metastatic | Surgery | 1.3 | Reported | mul | PFS | 7 |
| Miyake | 2018 | Japan | RTP, SC | 74 | - | PCa | Metastatic | Chemotherapy | 1.35 | Median | mul/uni | OS, BRFS | 6 |
| Kang | 2018 | South Korea | RTP, SC | 158 | 58.6 ± 10.6 | RCC | Metastatic | Targeted therapy | 1.2 | ROC | mul | OS, CSS | 7 |
| Canat | 2018 | Turkey | RTP, SC | 298 | 61.5 ± 13.2 | RCC | Non-metastatic | Surgery | 1.5 | ROC | uni | CSS | 6 |
| Wang | 2017 | China | RTP, SC | 438 | 70 (65–74) | PCa | Non-metastatic | Surgery | 1.325 | ROC | uni/mul | OS, BRFS | 7 |
| Lee | 2017 | South Korea | RTP, MI | 2965 | 55 (47–65) | RCC | Non-metastatic | Surgery | 1.5 | ROC | mul | OS, CSS, PFS | 7 |
| Lee | 2017 | South Korea | RTP, SC | 623 | 65 (56–72) | UTUC | Non-metastatic | Surgery | 1.5 | ROC | mul | OS, CSS, PFS | 7 |
| Ishihara | 2017 | Japan | RTP, SC | 118 | - | RCC | Metastatic | Surgery | 1.24 | ROC | mul | OS, CSS | 6 |
| Gorgel | 2017 | Turkey | RTP, SC | 153 | 61.7 ± 9.1 | BCa | Non-metastatic | Surgery | 1.3 | ROC | mul | OS, CSS | 6 |
| Cho | 2017 | South Korea | RTP, MI | 1049 | 69 (61–74) | UTUC | Non-metastatic | Surgery | 1.6 | ROC | mul/uni | OS, CSS, PFS | 7 |
| Bezan | 2015 | Austria | RTP, SC | 698 | 65 (56–73) | RCC | Non-metastatic | Surgery | 1.26 | ROC | mul | OS, PFS | 8 |
SQ, study quality according to the Newcastle-Ottawa scale; RTP, retrospective; SC, single center; MI, multi-institutional; UTUC, upper tract urothelial cancer; BCa, bladder cancer; PCa, prostate cancer; RCC, renal cell carcinoma; ROC, receiver-operating characteristic; OS, overall survival; CSS, cancer-specific cancer; PFS, progression-free survival; BRFS, biochemical recurrence-free survival.